Twenty years after its initial approval, trastuzumab remains a cornerstone in the treatment of patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC). Long-term follow-up from pivotal adjuvant trials has consistently ... ...

请注册登录后继续浏览